All News

Novo Nordisk proposes a $9 billion acquisition of Metsera, prompting responses from both Metsera and Pfizer amid ongoing merger discussions.

Eli Lilly invests $1.2 billion in Puerto Rico to enhance manufacturing capabilities, creating jobs and integrating advanced technologies for oral medicines.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

In today’s Pharmaceutical Executive Daily, we cover Eli Lilly’s partnership with NVIDIA to develop an AI supercomputer for drug discovery, a surge in biotech funding rounds and public offerings, and the FDA approval of Merck’s Winrevair for pulmonary arterial hypertension.

The agency says the new guidelines will simplify the requirements to bring biosimilars to market.

President Trump’s claims about $150 weight-loss medication are causing investors to question the importance of the contents of the current earnings reports.

Eli Lilly and NVIDIA unveil a groundbreaking AI supercomputer, revolutionizing drug discovery and accelerating patient care through advanced technology.

The acquisition aims to enhance drug development capabilities and accelerate clinical research innovation.

Zepbound will be offered as part of the LillyDirect program and will be available to patients for pick-up in over 4600 Walmart Pharmacies nationwide.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

In today’s Pharmaceutical Executive Daily, we cover the resignation of Organon CEO Kevin Ali following an internal investigation tied to Nexplanon sales, GSK’s $357 million agreement with Syndivia to expand its antibody-drug conjugate portfolio, and new guidance from the American College of Surgeons classifying obesity as a treatable condition.

GSK secures exclusive rights to EMP-012, a promising treatment for COPD, enhancing its respiratory pipeline and addressing unmet medical needs.

The FDA has approved a new single-injection, once-monthly maintenance regimen for Eli Lilly’s Omvoh (mirikizumab-mrkz), offering adults with moderately to severely active ulcerative colitis a more convenient dosing option that maintains proven efficacy and long-term remission outcomes.

Investments surge in the pharmaceutical sector as companies like Zag Bio and Hemab Therapeutics advance innovative treatments for rare diseases.

The FDA has updated the label for Merck’s Winrevair (sotatercept-csrk) following results from the Phase III ZENITH trial, confirming the therapy’s ability to reduce the risk of clinical worsening events in adults with pulmonary arterial hypertension.

Chris O’Dell, SVP of market solutions at Turquoise Health, discusses the impact on the various middle-men involved in drug-pricing.

In today’s Pharmaceutical Executive Daily, we cover the FDA approval of Bayer’s Lynkuet for menopausal hot flashes, new research suggesting Ozempic may reduce biological age, and Novartis’ $12 billion merger agreement to acquire Avidity Biosciences.

Organon faces leadership changes as CEO Kevin Ali resigns amid an investigation into improper sales practices involving Nexplanon.

GSK secures exclusive rights to Syndivia's promising ADC for metastatic castration-resistant prostate cancer, enhancing treatment options for patients.

Novartis acquires Avidity Biosciences to enhance its RNA therapeutics pipeline, targeting rare neuromuscular diseases with innovative therapies.

The group says that willpower alone won’t help most people.

Chris O’Dell, SVP of market solutions at Turquoise Health, details the ways that the President’s new program differs from previous programs.

Researchers reveal that GLP-1 medication Ozempic may reduce biological age, offering new hope in the fight against aging and related health issues.

Lynkuet, a hormone-free therapeutic option for hot flashes associated with menopause, is expected to be available in the United States in November 2025.

In today’s Pharmaceutical Executive Daily, we cover the emergence of TrumpRx and its implications for direct-to-consumer drug commercialization, new funding momentum across rare disease R&D, and Eli Lilly’s definitive agreement to acquire Aderum Biotechnologies.

GSK's Blenrep gains FDA approval, offering new hope for multiple myeloma patients with improved survival rates and community access.

Eli Lilly plans to acquire Adverum Biotechnologies for $3.56 per share, enhancing its portfolio in innovative genetic medicines for vision restoration.

AI transforms pharmaceutical operations by automating workflows, ensuring transparency, and enhancing compliance, driving efficiency and innovation in healthcare.